Shelton Capital Management Editas Medicine, Inc. Transaction History

Shelton Capital Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $84,864 - $134,742	-10,200 Reduced 7.02%	135,200 $1.2 Million
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $299,136 - $477,732	-24,600 Reduced 14.47%	145,400 $1.78 Million
Q1 2022 May 12, 2022	SELL	$14.08 - $27.63 $140,800 - $276,300	-10,000 Reduced 5.56%	170,000 $3.23 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $392,700 - $729,400	10,000 Added 5.88%	180,000 $7.39 Million
Q2 2021 Aug 12, 2021	BUY	$31.29 - $56.64 $1.19 Million - $2.15 Million	38,000 Added 28.79%	170,000 $9.63 Million
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $3.1 Million - $7.07 Million	78,000 Added 144.44%	132,000 $5.54 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $514,330 - $1.6 Million	19,000 Added 54.29%	54,000 $3.79 Million
Q1 2020 May 13, 2020	BUY	$14.88 - $32.78 $141,360 - $311,410	9,500 Added 37.25%	35,000 $694,000
Q3 2019 Nov 13, 2019	BUY	$22.49 - $26.81 $337,350 - $402,150	15,000 Added 142.86%	25,500 $580,000
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $215,040 - $291,480	10,500 New	10,500 $260,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

Stay updated on Shelton Capital Management with notifications on news.